David Wainer

MSN

Hype for Moderna's cancer vaccine is running ahead of the math

By: David Wainer

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion.

The Wall Street Journal

China is a Threat to Biotech’s Massive Bull Run

By: David Wainer

Plus, a defense-stock opportunity and timber cut down

MSN

China is a threat to biotech's massive bull run

By: David Wainer

Good morning, I'm filling in for Spencer Jakab. Markets are holding their breath until Kevin Warsh speaks at the Jackson Hole symposium later this morning.

Winston-Salem Journal

Butcher & Bull

By: David Wainer

Bourbon butterscotch creme brûlée at Butcher & Bull.

The Wall Street Journal

Jersey Mike’s Is Winning the Sandwich War. It Still Needs to Win Over Gen Z.

By: David Wainer

The chain’s affluent, older base gives it an edge. But to grow it also needs young customers.

MSN

Jersey Mike's is winning the sandwich war. It still needs to win over Gen Z.

By: David Wainer

Affluent older Americans might be the best customers in U.S. dining. They have savings, are relatively insulated from economic swings and, most valuable to a restaurant chain, prefer the familiar to the trendy.

The Wall Street Journal

The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.

By: David Wainer

Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

MSN

The cancer vaccine gold rush has begun. So has the race for picks and shovels.

By: David Wainer

The excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies.

The Wall Street Journal

Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness

By: David Wainer

Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

MSN

Heart disease, a historic strength for big pharma, becomes a weakness

By: David Wainer

There is a strange paradox haunting healthcare investing right now. Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.